NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) + Dex

NCT05288062: Phase 2: Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

Plasma Cell Myeloma

Recurrent Plasma Cell Myeloma

Refractory Plasma Cell Myeloma

Smoldering Plasma Cell Myeloma

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Drug (Dexamethasone) for the Treatment of Multiple Myeloma

This phase II trial studies the effect of immunomodulatory drug(s) in combination with a corticosteroid drug in treating patients with multiple myeloma or smoldering multiple myeloma. Immunomodulatory drugs such as lenalidomide and pomalidomide work through a variety of mechanisms to affect the function of the immune system. They are widely used as treatment for multiple myeloma and remain the backbone of therapy for both newly diagnosed patients and patients that have multiple myeloma that has come back after treatment (relapsed). Corticosteroid drugs like dexamethasone are strong anti-inflammatory agents that are also widely used to treat patients with multiple myeloma. This study may help doctors find out how patients respond to one treatment cycle of immunomodulatory drug(s) in combination with dexamethasone. This may help doctors determine which combinations of drugs work best in treating patients with multiple myeloma or smoldering multiple myeloma.

Sponsor:

Mayo Clinic

Collaborator:

National Cancer Institute (NCI)

---

ClinicalTrials.gov Identifier: NCT05288062

Official Title: Evaluating Mechanisms of Immunomodulator Sensitivity and Resistance in Multiple Myeloma

First Posted: March 18, 2022

Click here for details on ClinicalTrials.Gov

---

Procedure: Bone Marrow Biopsy

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Pomalidomide

---

Locations

United States, Arizona

United States, Arizona

United States, Minnesota